| Date Filed | Type | Description |
| 02/10/2023 |
SC 13G/A
| Satter Muneer A reports a 8.2% stake in Akebia Therapeutics, Inc. |
| 02/10/2023 |
SC 13G/A
| Satter Muneer A reports a 6.7% stake in Aadi Bioscience, Inc. |
| 12/19/2022 |
SC 13G
| Satter Muneer A reports a 7.5% stake in Akebia Therapeutics, Inc. |
| 10/04/2022 |
SC 13G
| Satter Muneer A reports a 5.3% stake in Aadi Bioscience, Inc. |
| 07/18/2022 |
SC 13D
| Satter Muneer A reports a 10.4% stake in Annexon, Inc. |
| 02/10/2022 |
SC 13G/A
| Satter Muneer A reports a 4.7% stake in Assembly Biosciences, Inc. |
| 11/12/2021 |
SC 13D/A
| Satter Muneer A reports a 1.8% stake in Aadi Bioscience, Inc. |
| 02/12/2021 |
SC 13G/A
| Satter Muneer A reports a 6.7% stake in Assembly Biosciences, Inc. |
| 02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2021 |
SC 13G
| Satter Muneer A reports a 5.1% stake in Annexon, Inc. |
| 01/08/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/04/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/09/2020 |
SC 13D/A
| Satter Muneer A reports a 19.9% stake in Aileron Therapeutics, Inc. |
| 02/12/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/11/2019 |
SC 13D/A
| Satter Muneer A reports a 19.9% stake in Aileron Therapeutics, Inc. |
| 04/10/2019 |
SC 13D
| Satter Muneer A reports a 25.1% stake in Aileron Therapeutics, Inc. |
| 02/13/2019 |
SC 13G/A
| Satter Muneer A reports a 7% stake in Albireo Pharma, Inc. |
| 02/13/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/11/2019 |
SC 13D/A
| Satter Muneer A reports a 2.6% stake in Akebia Therapeutics, Inc. |
| 01/11/2019 |
SC 13D/A
| Satter Muneer A reports a 13.9% stake in Aerpio Pharmaceuticals, Inc. |
| 09/18/2018 |
SC 13D/A
| Satter Muneer A reports a 0.5% stake in Vital Therapies, Inc. |
| 07/03/2018 |
SC 13D/A
| Satter Muneer A reports a 13.1% stake in Aerpio Pharmaceuticals, Inc. |
| 07/03/2018 |
SC 13D/A
| Satter Muneer A reports a 5.4% stake in Akebia Therapeutics, Inc. |
| 06/08/2018 |
SC 13D/A
| Satter Muneer A reports a 27.2% stake in Vital Therapies, Inc. |
| 02/09/2018 |
SC 13G/A
| Satter Muneer A reports a 5.9% stake in Edge Therapeutics, Inc. |
| 02/09/2018 |
SC 13G/A
| Satter Muneer A reports a 7.7% stake in Albireo Pharma, Inc. |
| 07/14/2017 |
SC 13D
| Satter Muneer A reports a 6.5% stake in Akebia Therapeutics, Inc. |
| 05/30/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 04/25/2017 |
SC 13G
| Edge Therapeutics, Inc. reports a 5.8% stake in Edge Therapeutics, Inc. |
| 04/04/2017 |
SC 13D
| VITAL THERAPIES INC reports a 26.9% stake in Vital Therapies, Inc. |
| 03/27/2017 |
SC 13D
| ZETA ACQUISITION CORP II reports a 12% stake in Aerpio Pharmaceuticals, Inc. |
| 02/13/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
| 02/13/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
| 02/13/2017 |
SC 13G/A
| Akebia Therapeutics, Inc. reports a 5.2% stake in Akebia Therapeutics, Inc. |
|